Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioAtla (BCAB)
NASDAQ:BCAB
BioAtla (BCAB) Stock Price & Analysis
196 Followers
BCAB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.24 - $4.02
Previous Close$1.35
Volume923.49K
Average Volume (3M)822.67K
Market Cap
$64.96M
Enterprise Value-$13.75M
Total Cash (Recent Filing)$80.63M
Total Debt (Recent Filing)$1.92M
Price to Earnings (P/E)―
Beta3.06
Next Earnings
Aug 08, 2024EPS Estimate
-$0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.49
Shares Outstanding48,115,918
10 Day Avg. Volume443,118
30 Day Avg. Volume822,671
Standard Deviation0.36
R-Squared0.02
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.46
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.12
Forecast
1Y Price Target
$8.25Price Target Upside525.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
BioAtla News
Bulls Say, Bears Say
Bulls Say
Clinical Trial AdvancementsBioAtla's conditionally active biologics are showing enhanced activity in tumors, which could lead to improved efficacy in treating cancer.
Drug Development MilestonesBioAtla is preparing to initiate a Phase 3 study for a treatment targeting BRAF-mutated melanoma, a patient group that has shown significant benefits in past studies.
Financial Stability And Growth ProspectsWith a healthy cash reserve and multiple potential partnerships on the horizon, BioAtla is well-positioned for future development and commercialization efforts.
Bears Say
Analyst Price Target ChangeAnalyst lowers price target for BioAtla to $5 from $12 due to uncertainty in BA3011 development in NSCLC, removing its revenues from the model
Company Strategy ShiftThe company decided to prioritize its development in HNSCC and put melanoma on the back burner
Drug Development DelaysMecbotamab vedotin (BA3011) studies are advancing slower than expected
---
Ownership Overview
24.22% Insiders
13.02% Mutual Funds
26.72% Other Institutional Investors
36.04% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BCAB FAQ
What was BioAtla’s price range in the past 12 months?
BioAtla lowest stock price was $1.24 and its highest was $4.02 in the past 12 months.
What is BioAtla’s market cap?
Currently, no data Available
When is BioAtla’s upcoming earnings report date?
BioAtla’s upcoming earnings report date is Aug 08, 2024 which is in 36 days.
How were BioAtla’s earnings last quarter?
BioAtla released its earnings results on May 14, 2024. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$0.542 by $0.062.
Is BioAtla overvalued?
According to Wall Street analysts BioAtla’s price is currently Undervalued.
Does BioAtla pay dividends?
BioAtla does not currently pay dividends.
What is BioAtla’s EPS estimate?
BioAtla’s EPS estimate is -$0.45.
How many shares outstanding does BioAtla have?
BioAtla has 48,115,917 shares outstanding.
What happened to BioAtla’s price movement after its last earnings report?
BioAtla reported an EPS of -$0.48 in its last earnings report, beating expectations of -$0.542. Following the earnings report the stock price went up 14.943%.
Which hedge fund is a major shareholder of BioAtla?
Among the largest hedge funds holding BioAtla’s share is Woodline Partners LP. It holds BioAtla’s shares valued at 458K.
---
BioAtla Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.25 (525.00% Upside)
$8.25 (525.00% Upside)
Hedge Fund Trend
Increased
By 48.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.00%
12-Months-Change
Fundamentals
Return on Equity
-115.68%
Trailing 12-Months
Asset Growth
-56.39%
Trailing 12-Months
Company Description
BioAtla
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
---
BCAB Earnings Call
Q1 2024
0:00 / 0:00
---
BCAB Stock 12 Month Forecast
Average Price Target
$8.25
▲(525.00% Upside)
Technical Analysis
Atara Biotherapeutics
―
Adaptimmune Therapeutics
―
Kura Oncology
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering BCAB
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-34.52%
reiterated a buy rating 2 months ago
Copying Arthur He CFA's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -34.52% per trade.
---